De novo malignant solitary fibrous tumor of the kidney
© Hsieh et al; licensee BioMed Central Ltd. 2011
Received: 10 August 2011
Accepted: 5 October 2011
Published: 5 October 2011
The kidney is a relatively infrequent site for solitary fibrous tumor (SFT). Among the previously reported cases, only two cases of malignant renal SFT developing via dedifferentiation from a pre-existing benign SFT have been reported. Here we reported a case of de novo malignant renal SFT clinically diagnosed as renal cell carcinoma in a 50-year-old woman. The tumor was circumscribed but unencapsulated and showed obvious hemorrhagic necrosis. Microscopically, the tumor was composed of patternless sheets of alternating hypercellular and hypocellular areas of spindle cells displaying mild to moderate nuclear atypia, frequent mitoses up to 8 per 10 high power fields, and a 20% Ki-67 proliferative index. Immunohistochemical studies revealed reactivity for CD34, CD99 and vimentin, with no staining for all other markers, confirming the diagnosis of SFT. No areas of dedifferentiation were seen after extensive sampling. Based on the pathologic and immunohistochemical features, a diagnosis of de novo malignant renal SFT was warranted. Our report expands the spectrum of malignant progression in renal SFTs. Even though this patient has been disease-free for 30 months, long-term follow-up is still mandatory.
Keywordssolitary fibrous tumor kidney malignant de novo dedifferentiation CD34
Solitary fibrous tumors (SFTs) are distinctive mesenchymal tumors most commonly described as pleural-based lesions; however they can develop at any extrapleural anatomic site . Although the clinical course of SFTs is rather unpredictable, the prognosis of SFTs is generally favorable. It is estimated that 10% to 15% of intrathoracic SFTs and up to 10% of extrathoracic SFTs will recur and/or metastasize [2, 3], therefore SFT is regarded as an "intermediate malignant, rarely metastasizing" neoplasm . Microscopic features associated with malignancy in both intrathoracic and extrathoracic SFTs include nuclear atypia, increased cellularity and more than 4 mitoses per 10 high power fields [4, 5]. An additional factor conferring a worse prognosis in SFTs is dedifferentiation or sarcomatous overgrowth, which represents an abrupt transition to a morphologically anaplastic component . The kidney is a relatively infrequent site for SFT, with at least 36 cases reported in a review article . The vast majority of renal SFTs are histologically benign and only two cases of malignant renal SFTs developing via dedifferentiation or sarcomatous overgrowth from a pre-existing benign SFT have been reported [7, 8]. Here we report the first case of de novo malignant renal SFT without dedifferentiation and thus expand the spectrum of malignant progression in renal SFTs.
SFT is a relatively uncommon but distinctive mesenchymal neoplasm, originally described in the pleura cavity and later reported to occur ubiquitously . Although the histogenesis of SFT remains undetermined, recent studies strongly favor a primitive mesenchymal or perivascular cell origin . The kidney is a relatively infrequent site for SFT, with approximately at least 36 cases of renal SFT reported in a review article . Clinically, these cases were frequently considered to be malignant due to their large tumor size by physical examinations and radiographic studies. Symptoms do not differ from those reported by patients with renal cell carcinoma. Hypoglycemia, which is a rare symptom in intrathoracic and extrathoracic SFTs, was not reported in any renal SFTs including our case .
Comparsion of the clinicopathologic features of malignant renal solitary fibrous tumor
Fine et al.
Margo et al.
12 × 10 × 7.5 cm
9 cm, with a distinct 3-cm nodule
9 × 9 × 6 cm
Infiltrative with invasion beyond the renal capsule
10% benign SFT 90% dedifferentiation
70% benign SFT 30% dedifferentiation
De novo malignant SFT
Marked in areas of dedifferentiation
Marked in areas of dedifferentiation
Mild to moderate
Ki-67 proliferative index
Loss of expression in areas of dedifferentiation
Multiple lung nodules 4 month after nephrectomy
15 months, NED
30 months, NED
The criteria for clinical malignancy in intrathoracic SFT, first proposed by England et al. in 1989, include increased cellularity, pleomorphism, mitotic count more than 4 per 10 high power fields, necrosis, hemorrhage, size more than 10 cm, non-pedunculated and atypical locations (parietal pleura, pulmonary parenchyma) . The diagnostic criteria for malignant extrathoracic SFTs are purely microscopic and include increased cellularity, pleomorphism and mitotic count more than 4 per 10 high power fields [4, 11]. Currently the impact of tumor characteristics (size, hemorrhage, necrosis and location) in predicting clinical malignancy in extrathoracic SFTs remains to be investigated. Our case fulfilled the diagnostic criteria for malignant extrathoracic SFTs. Additionally, the presence of hemorrhage and necrosis and a 20% Ki-67 proliferative index further supports a diagnosis of malignant renal SFT.
SFTs show a wide variety of microscopic growth patterns and should be distinguished from benign and malignant spindle cell tumors. Positive immunoreactivity for CD34 and CD99 is characteristic of SFT, and highly valuable in differentiating from other mesenchymal tumors [2, 4]. However the expression of CD34 and CD99 may be decreased or absent in areas with marked atypia or dedifferentiation [8, 12]. Genetic analyses of SFT to date have not found consistent and characteristic cytogenetic abnormalities that can be used an ancillary diagnostic marker. Missense mutation of platelet-derived growth factor receptor-β (PDGFR-β) has been reported in 2 of 88 pleuro-pulmonary SFTs , but we did not detect PDGFR-β mutation in our case (data not shown).
The prognosis of extrapleural SFTs is more unpredictable than that of pleural tumors due to lack of large-scale studies. The clinical outcomes were rather strikingly different in the two malignant renal SFTs with dedifferentiation. While a patient developed multiple small lung nodules 4 months post-operatively , the other patient was disease-free after 15 months of follow-up . Our patient has been well without evidence of recurrence or metastasis for 30 months. Some studies indicated that extrapleural SFTs had similar prognosis as the pleural counterpart, and a tumor with malignant histological feature was associated with recurrence and metastasis [3, 14], but other studies showed that extrapleural SFTs tended to have a favorable outcome than pleural ones, even those with malignant histological features [11, 15]. Studies also showed that deep-seated locations, over-expression of p53 and p16, loss of CD34 immunostaining and the presence of dedifferentiated areas may indicate more aggressive behaviors . Complete surgical excision and long-term follow-up are generally recommended for patients with extrapleural SFTs . Besides, due to the rich vascularity and possible origin from pericytes, antiangiogenic therapy, especially for the advanced cases is also under clinical investigation .
Written informed consent was obtained from the patient for publication of this case report and accompanying images. Submission of this case report was approved by Institutional Review Board (IRB) of Chang Gung Memorial Hospital, Tao-Yuan, Taiwan. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
List of abbreviations
solitary fibrous tumor
The authors appreciate Drs. Jonathan I. Epstein and Elizabeth Montgomery at the Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA for confirming our diagnosis.
- Chan JK: Solitary fibrous tumour--everywhere, and a diagnosis in vogue. Histopathology. 1997, 31: 568-76. 10.1046/j.1365-2559.1997.2400897.x.View ArticlePubMed
- Weiss SW, Goldblum JR: Soft tissue tumors of intermediate malignancy of uncertain type. Soft Tissue Tumor. Edited by: Weiss SW, Goldblum JR. 2008, Philadephia: Mosby Elsevier, 1093-1160. 5
- Vallat-Decouvelaere AV, Dry SM, Fletcher CD: Atypical and malignant solitary fibrous tumors in extrathoracic locations: evidence of their comparability to intra-thoracic tumors. Am J Surg Pathol. 1998, 22: 1501-11. 10.1097/00000478-199812000-00007.View ArticlePubMed
- Guillou LFJ, Fletcher CDM, Mandahi N: Extrapleural solitary fibrous tumour and hemangiopericytoma. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. Edited by: Fletcher CDM, Unni KK, Mertens F. 2002, Lyon: IARCPress, 86-90.
- England DM, Hochholzer L, McCarthy MJ: Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol. 1989, 13: 640-58. 10.1097/00000478-198908000-00003.View ArticlePubMed
- Mosquera JM, Fletcher CD: Expanding the spectrum of malignant progression in solitary fibrous tumors: a study of 8 cases with a discrete anaplastic component--is this dedifferentiated SFT?. Am J Surg Pathol. 2009, 33: 1314-21. 10.1097/PAS.0b013e3181a6cd33.View ArticlePubMed
- Magro G, Emmanuele C, Lopes M, Vallone G, Greco P: Solitary fibrous tumour of the kidney with sarcomatous overgrowth. Case report and review of the literature. APMIS. 2008, 116: 1020-5. 10.1111/j.1600-0463.2008.01012.x.View ArticlePubMed
- Fine SW, McCarthy DM, Chan TY, Epstein JI, Argani P: Malignant solitary fibrous tumor of the kidney: report of a case and comprehensive review of the literature. Arch Pathol Lab Med. 2006, 130: 857-61.PubMed
- Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J: ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 2010, 12: R56-10.1186/bcr2615.PubMed CentralView ArticlePubMed
- Ide F, Obara K, Mishima K, Saito I, Kusama K: Ultrastructural spectrum of solitary fibrous tumor: a unique perivascular tumor with alternative lines of differentiation. Virchows Arch. 2005, 446: 646-52. 10.1007/s00428-005-1261-z.View ArticlePubMed
- Hasegawa T, Matsuno Y, Shimoda T, Hasegawa F, Sano T, Hirohashi S: Extrathoracic solitary fibrous tumors: their histological variability and potentially aggressive behavior. Hum Pathol. 1999, 30: 1464-73. 10.1016/S0046-8177(99)90169-7.View ArticlePubMed
- Yokoi T, Tsuzuki T, Yatabe Y, Suzuki M, Kurumaya H, Koshikawa T, Kuhara H, Kuroda M, Nakamura N, Nakatani Y, et al.: Solitary fibrous tumour: significance of p53 and CD34 immunoreactivity in its malignant transformation. Histopathology. 1998, 32: 423-32. 10.1046/j.1365-2559.1998.00412.x.View ArticlePubMed
- Schirosi L, Lantuejoul S, Cavazza A, Murer B, Yves Brichon P, Migaldi M, Sartori G, Sgambato A, Rossi G: Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR. Am J Surg Pathol. 2008, 32: 1627-42. 10.1097/PAS.0b013e31817a8a89.View ArticlePubMed
- Brunnemann RB, Ro JY, Ordonez NG, Mooney J, El-Naggar AK, Ayala AG: Extrapleural solitary fibrous tumor: a clinicopathologic study of 24 cases. Mod Pathol. 1999, 12: 1034-42.PubMed
- Morimitsu Y, Nakajima M, Hisaoka M, Hashimoto H: Extrapleural solitary fibrous tumor: clinicopathologic study of 17 cases and molecular analysis of the p53 pathway. APMIS. 2000, 108: 617-25. 10.1034/j.1600-0463.2000.d01-105.x.View ArticlePubMed
- Park MS, Araujo DM: New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. Curr Opin Oncol. 2009, 21: 327-31. 10.1097/CCO.0b013e32832c9532.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.